Jefferies London 2026: APOL1-mediated kidney disease affects over 1 million people in the United States - Maze Therapeutics hopes to deliver a solution
CEO Jason Coloma describes the unmet need in this area - which affects younger people compared to most other chronic kidney conditions. He walks us through MZE829, which just completed enrollment the phase 2 HORIZON trial and will have data in early 2027.
Coverage brought to you by










.png)
